| Title: |
Outcomes of Older Primary Kidney Transplant Recipients by Induction Agent and High-risk Viral Discordance Status in the United States |
| Authors: |
Randi J. Ryan, MD; Andrew J. Bentall, MD; Naim Issa, MD; Patrick G. Dean, MD; Byron H. Smith, MS, PhD; Mark D. Stegall, MD; Samy M. Riad, MD, MS, FAST |
| Source: |
Transplantation Direct, Vol 10, Iss 10, p e1698 (2024) |
| Publisher Information: |
Wolters Kluwer |
| Publication Year: |
2024 |
| Collection: |
Directory of Open Access Journals: DOAJ Articles |
| Subject Terms: |
Surgery; RD1-811 |
| Description: |
Background. The impact of induction type or high-risk viral discordance on older kidney transplant recipients is unclear. Herein, we analyzed the association between induction type, viral discordance, and outcomes for older recipients. Methods. We analyzed the Scientific Registry of Transplant Recipients standard analysis file for all primary kidney transplant recipients older than 55 y who were transplanted between 2005 and 2022. All transplants were crossmatch negative and ABO-compatible. Recipients were discharged on tacrolimus and mycophenolate ± steroids. Recipients were categorized into 3 groups by induction received: rabbit antithymocyte globulin (r-ATG; N = 51 079), interleukin-2 receptor antagonist (IL-2RA; N = 22 752), and alemtuzumab (N = 13 465). Kaplan-Meier curves were generated for recipient and graft survival, and follow-up was censored at 10 y. Mixed-effect Cox proportional hazard models examined the association between induction type, high-risk viral discordance, and outcomes of interest. Models were adjusted for pertinent recipient and donor characteristics. Results. Induction type did not predict recipient survival in the multivariable model, whereas Epstein-Barr virus high-risk discordance predicted 14% higher mortality (1.14 [1.07-1.21], P < 0.01). In the multivariable model for death-censored graft survival, alemtuzumab, but not IL-2RA, was associated with an increased risk of graft loss (1.18 [1.06-1.29], P < 0.01) compared with r-ATG. High-risk cytomegalovirus discordance predicted 10% lower death-censored graft survival (1.10 [1.01-1.19], P < 0.02). Live donor and preemptive transplantation were favorable predictors of survival. Conclusions. In this large cohort of older transplant recipients, alemtuzumab, but not IL-2RA, induction was associated with an increased risk of graft loss compared with r-ATG. Cytomegalovirus and Epstein-Barr virus high-risk viral discordance portended poor graft and recipient survival, respectively. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001698; https://doaj.org/toc/2373-8731; https://doaj.org/article/215042923abb4804be8e220a3969c070 |
| DOI: |
10.1097/TXD.0000000000001698 |
| Availability: |
https://doi.org/10.1097/TXD.0000000000001698; https://doaj.org/article/215042923abb4804be8e220a3969c070 |
| Accession Number: |
edsbas.93160EB1 |
| Database: |
BASE |